Tracking treatment for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tracks people with advanced prostate cancer who are getting a new treatment called lutetium (177Lu) vipivotide tetraxetan. The goal is to gather real-world information about how this treatment works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced prostate cancer (cancer that has spread).
- Your cancer cells show a marker called PSMA, which the treatment targets.
- You have received at least one dose of lutetium (177Lu) vipivotide tetraxetan.
- You are not currently in another experimental study or have not been in one within the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows men with advanced prostate cancer who are receiving a new radioactive treatment called lutetium (177Lu) vipivotide tetraxetan. The goal is to see how well the treatment works in everyday practice, and to gather information on safety and effectiveness.
This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
This study tests a new treatment called 177Lu-PSMA given after standard therapy (surgery or radiation) to see if it can prevent prostate cancer from coming back. It is for patients with high or very high-risk prostate cancer that hasn't spread yet.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.